Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

GoPro, Krispy Kreme, and Kohl’s surge as meme stock mania returns. Retail traders drive volatility in a high-liquidity, ...

Wall Street's biggest bull sees tech and AI driving an 11% stock gain, fueled by strong fundamentals, M&A activity, and ...

Pfizer Inc. (NYSE:PFE) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. Pfizer Inc. (NYSE:PFE) hasn’t performed well in recent years, with its stock declining more than 26% over ...

Shares of Johnson & Johnson climbed 6.8% in morning trading, enough to pace the S&P 500 index's SPX gainers. They were also headed for their biggest one-day gain and best postearnings reaction since ...

Pfizer (PFE), a global pharmaceutical giant that was once a pandemic darling, is now facing turbulence. Following a period of extraordinary vaccine-driven revenue, the company now faces a more ...

A retirement-ready portfolio consists of reliable, income-generating stocks that quietly compound over time. Realty Income (O ...

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Arexvy is currently approved for use in all individuals aged 60 and older, as well as for high-risk individuals aged 50-59.

PBF Energy Inc. (NYSE: PBF) is one of the 10 Energy Stocks with Insider Buying in 2025. Despite the successful completion of ...

In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite contro ...

Pfizer faces adjusted financial forecasts as analysts lower earnings expectations for FY2025, signaling cautious optimism.